BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020;50:e13338. [PMID: 32589264 DOI: 10.1111/eci.13338] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Gaspar R, Castelo Branco C, Macedo G. Liver and COVID-19: From care of patients with liver diseases to liver injury. World J Hepatol 2021; 13(10): 1367-1377 [PMID: 34786172 DOI: 10.4254/wjh.v13.i10.1367] [Reference Citation Analysis]
2 Elfeki MA, Robles J, Akhtar Z, Ullah F, Ganapathiraju I, Tran C, Inman C, Collin SM, Rosa R. Impact of Fibrosis-4 Index Prior to COVID-19 on Outcomes in Patients at Risk of Non-alcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 34173917 DOI: 10.1007/s10620-021-07120-0] [Reference Citation Analysis]
3 Asemota J, Aduli F. The Impact of Nonalcoholic Fatty Liver Disease on the Outcomes of Coronavirus Disease 2019 Infection. Clinical Liver Disease 2022;19:29-31. [DOI: 10.1002/cld.1169] [Reference Citation Analysis]
4 Nasa P, Alexander G. COVID-19 and the liver: What do we know so far? World J Hepatol 2021; 13(5): 522-532 [PMID: 34131467 DOI: 10.4254/wjh.v13.i5.522] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Xu Y, Yang X, Bian H, Xia M. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis 2021;20:126. [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z] [Reference Citation Analysis]
6 Toor R, Chana I. Exploring diet associations with Covid-19 and other diseases: a Network Analysis-based approach. Med Biol Eng Comput 2022. [PMID: 35171411 DOI: 10.1007/s11517-022-02505-3] [Reference Citation Analysis]
7 Sikkema BJB, Sint Nicolaas JJ, van Wijngaarden PP. No association between COVID-19 related liver injury and the course of disease: a retrospective study. Scand J Gastroenterol 2021;56:68-71. [PMID: 33119428 DOI: 10.1080/00365521.2020.1842489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Cordeiro A, Ribamar A, Ramalho A. ADIPOSE TISSUE DYSFUNCTION AND MAFLD IN OBESITY ON THE SCENE OF COVID-19. Clin Res Hepatol Gastroenterol 2021;:101807. [PMID: 34543756 DOI: 10.1016/j.clinre.2021.101807] [Reference Citation Analysis]
9 Yan T, Xiao R, Wang N, Shang R, Lin G. Obesity and severe coronavirus disease 2019: molecular mechanisms, paths forward, and therapeutic opportunities. Theranostics 2021;11:8234-53. [PMID: 34373739 DOI: 10.7150/thno.59293] [Reference Citation Analysis]
10 Hegyi PJ, Váncsa S, Ocskay K, Dembrovszky F, Kiss S, Farkas N, Erőss B, Szakács Z, Hegyi P, Pár G. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis. Front Med (Lausanne) 2021;8:626425. [PMID: 33777974 DOI: 10.3389/fmed.2021.626425] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Mikolasevic I, Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S. Liver disease in the era of COVID-19: Is the worst yet to come? World J Gastroenterol 2021; 27(36): 6039-6052 [PMID: 34629818 DOI: 10.3748/wjg.v27.i36.6039] [Reference Citation Analysis]
12 Sazgarnejad S, Yazdanpanah N, Rezaei N. Anti-inflammatory effects of GLP-1 in patients with COVID-19. Expert Rev Anti Infect Ther 2021;:1-9. [PMID: 34348067 DOI: 10.1080/14787210.2021.1964955] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
14 Ilias I, Goulas S, Zabuliene L. Polycystic ovary syndrome: Pathways and mechanisms for possible increased susceptibility to COVID-19. World J Clin Cases 2021; 9(12): 2711-2720 [PMID: 33969054 DOI: 10.12998/wjcc.v9.i12.2711] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Port JR, Adney DR, Schwarz B, Schulz JE, Sturdevant DE, Smith BJ, Avanzato VA, Holbrook MG, Purushotham JN, Stromberg KA, Leighton I, Bosio CM, Shaia C, Munster VJ. Western diet increases COVID-19 disease severity in the Syrian hamster. bioRxiv 2021:2021. [PMID: 34159329 DOI: 10.1101/2021.06.17.448814] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Nabil A, Elshemy MM, Uto K, Soliman R, Hassan AA, Shiha G, Ebara M. Coronavirus (SARS-CoV-2) in gastroenterology and its current epidemiological situation: An updated review until January 2021. EXCLI J 2021;20:366-85. [PMID: 33746667 DOI: 10.17179/excli2021-3417] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Di Ciaula A, Krawczyk M, Filipiak KJ, Geier A, Bonfrate L, Portincasa P. Noncommunicable diseases, climate change and iniquities: What COVID-19 has taught us about syndemic. Eur J Clin Invest 2021;51:e13682. [PMID: 34551123 DOI: 10.1111/eci.13682] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Vázquez-Medina MU, Cerda-Reyes E, Galeana-Pavón A, López-Luna CE, Ramírez-Portillo PM, Ibañez-Cervantes G, Torres-Vázquez J, Vargas-De-León C. Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019. Hepatol Commun 2022. [PMID: 35438253 DOI: 10.1002/hep4.1957] [Reference Citation Analysis]
19 Anirvan P, Singh SP, Giammarino A, Satapathy SK. Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence. World J Hepatol 2021; 13(8): 916-925 [PMID: 34552698 DOI: 10.4254/wjh.v13.i8.916] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ali A, Hasan M, Hamed S, Elhamy A. Hepatic steatosis: a risk factor for increased COVID-19 prevalence and severity-a computed tomography study. Egypt Liver J 2021;11:61. [PMID: 34777870 DOI: 10.1186/s43066-021-00131-6] [Reference Citation Analysis]
21 Miele L, Napodano C, Cesario A, De Magistris A, Pocino K, Basile U, Rapaccini GL, Gasbarrini A, Grieco A. COVID-19, adaptative immune response and metabolic-associated liver disease. Liver Int 2021;41:2560-77. [PMID: 34555255 DOI: 10.1111/liv.15061] [Reference Citation Analysis]
22 Yakhchali M, Taghipour Z, Mirabzadeh Ardakani M, Alizadeh Vaghasloo M, Vazirian M, Sadrai S. Cinnamon and its possible impact on COVID-19: The viewpoint of traditional and conventional medicine. Biomed Pharmacother 2021;143:112221. [PMID: 34563952 DOI: 10.1016/j.biopha.2021.112221] [Reference Citation Analysis]
23 Ziaee A, Azarkar G, Ziaee M. Role of fatty liver in coronavirus disease 2019 patients' disease severity and hospitalization length: a case-control study. Eur J Med Res 2021;26:115. [PMID: 34565475 DOI: 10.1186/s40001-021-00590-y] [Reference Citation Analysis]
24 Hu X, Sun L, Guo Z, Wu C, Yu X, Li J. Management of COVID-19 Patients with Chronic Liver Diseases and Liver Transplants. Ann Hepatol 2021;:100653. [PMID: 34929350 DOI: 10.1016/j.aohep.2021.100653] [Reference Citation Analysis]
25 Jeyakumar SM, Vajreswari A. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World J Clin Cases 2021; 9(31): 9333-9349 [PMID: 34877270 DOI: 10.12998/wjcc.v9.i31.9333] [Reference Citation Analysis]
26 Alarcon PC, Damen MSMA, Madan R, Deepe GS Jr, Spearman P, Way SS, Divanovic S. Adipocyte inflammation and pathogenesis of viral pneumonias: an overlooked contribution. Mucosal Immunol 2021. [PMID: 33958704 DOI: 10.1038/s41385-021-00404-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Galiero R, Pafundi PC, Simeon V, Rinaldi L, Perrella A, Vetrano E, Caturano A, Alfano M, Beccia D, Nevola R, Marfella R, Sardu C, Coppola C, Scarano F, Maggi P, De Lucia Sposito P, Vocciante L, Rescigno C, Sbreglia C, Fraganza F, Parrella R, Romano A, Calabria G, Polverino B, Pagano A, Bologna C, Amitrano M, Esposito V, Coppola N, Maturo N, Adinolfi LE, Chiodini P, Sasso FC; COVOCA Study Group. Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study. PLoS One 2020;15:e0243700. [PMID: 33301529 DOI: 10.1371/journal.pone.0243700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Calapod OP, Marin AM, Onisai M, Tribus LC, Pop CS, Fierbinteanu-Braticevici C. The Impact of Increased Fib-4 Score in Patients with Type II Diabetes Mellitus on Covid-19 Disease Prognosis. Medicina (Kaunas) 2021;57:434. [PMID: 33946377 DOI: 10.3390/medicina57050434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kaviani M, Keshtkar S, Soleimanian S, Sabet Sarvestani F, Azarpira N, Pakbaz S. Susceptibility to Metabolic Diseases in COVID-19: To be or Not to be an Issue. Front Mol Biosci 2022;9:803314. [DOI: 10.3389/fmolb.2022.803314] [Reference Citation Analysis]
30 Shanmugam H, Di Ciaula A, Di Palo DM, Molina-Molina E, Garruti G, Faienza MF, vanErpecum K, Portincasa P. Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver. Eur J Clin Invest 2021;51:e13597. [PMID: 34032283 DOI: 10.1111/eci.13597] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
31 Nasa P, Alexander G. COVID-19 and the liver: What do we know so far? World J Hepatol 2021;13:522-32. [PMID: 34131467 DOI: 10.4254/wjh.v13.i5.522] [Reference Citation Analysis]
32 Mohammad S, Aziz R, Al Mahri S, Malik SS, Haji E, Khan AH, Khatlani TS, Bouchama A. Obesity and COVID-19: what makes obese host so vulnerable? Immun Ageing 2021;18:1. [PMID: 33390183 DOI: 10.1186/s12979-020-00212-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 23.0] [Reference Citation Analysis]
33 Mohammed A, Paranji N, Chen PH, Niu B. COVID-19 in Chronic Liver Disease and Liver Transplantation: A Clinical Review. J Clin Gastroenterol 2021;55:187-94. [PMID: 33394628 DOI: 10.1097/MCG.0000000000001481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Port JR, Adney DR, Schwarz B, Schulz JE, Sturdevant DE, Smith BJ, Avanzato VA, Holbrook MG, Purushotham JN, Stromberg KA, Leighton I, Bosio CM, Shaia C, Munster VJ. High-Fat High-Sugar Diet-Induced Changes in the Lipid Metabolism Are Associated with Mildly Increased COVID-19 Severity and Delayed Recovery in the Syrian Hamster. Viruses 2021;13:2506. [DOI: 10.3390/v13122506] [Reference Citation Analysis]
35 Vasques-Monteiro IML, Souza-Mello V. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight. World J Gastroenterol 2021; 27(16): 1738-1750 [PMID: 33967554 DOI: 10.3748/wjg.v27.i16.1738] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Dongiovanni P, Meroni M, Longo M, Fracanzani AL. MAFLD in COVID-19 patients: an insidious enemy. Expert Review of Gastroenterology & Hepatology 2020;14:867-72. [DOI: 10.1080/17474124.2020.1801417] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
37 Singh A, Hussain S, Antony B. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. Diabetes Metab Syndr 2021;15:813-22. [PMID: 33862417 DOI: 10.1016/j.dsx.2021.03.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Gracia-Ramos AE, Jaquez-Quintana JO, Contreras-Omaña R, Auron M. Liver dysfunction and SARS-CoV-2 infection. World J Gastroenterol 2021; 27(26): 3951-3970 [PMID: 34326607 DOI: 10.3748/wjg.v27.i26.3951] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Chen L, Fan Z, Cheng J. Reply. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01095-8. [PMID: 34634488 DOI: 10.1016/j.cgh.2021.10.009] [Reference Citation Analysis]
40 Chen JC, Xie TA, Lin ZZ, Li YQ, Xie YF, Li ZW, Guo XG. Identification of Key Pathways and Genes in SARS-CoV-2 Infecting Human Intestines by Bioinformatics Analysis. Biochem Genet 2021. [PMID: 34787756 DOI: 10.1007/s10528-021-10144-w] [Reference Citation Analysis]
41 Parlak S, Çıvgın E, Beşler MS, Kayıpmaz AE. The effect of hepatic steatosis on COVID-19 severity: Chest computed tomography findings. Saudi J Gastroenterol 2021;27:105-10. [PMID: 33642355 DOI: 10.4103/sjg.sjg_540_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Di Sessa A, Lanzaro F, Zarrilli S, Picone V, Guarino S, Miraglia del Giudice E, Marzuillo P. COVID-19 and pediatric fatty liver disease: Is there interplay? World J Gastroenterol 2021; 27(22): 3064-3072 [PMID: 34168408 DOI: 10.3748/wjg.v27.i22.3064] [Reference Citation Analysis]
43 Lukas H, Xu C, Yu Y, Gao W. Emerging Telemedicine Tools for Remote COVID-19 Diagnosis, Monitoring, and Management. ACS Nano 2020;14:16180-93. [PMID: 33314910 DOI: 10.1021/acsnano.0c08494] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
44 Campos-Murguía A, Román-Calleja BM, González-Regueiro JA, Hurtado-Díaz-de-León I, Solís-Ortega AA, Flores-García NC, García-Juárez I, Ruiz-Margáin A, Macías-Rodríguez RU. Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World J Gastroenterol 2021; 27(33): 5502-5519 [PMID: 34588748 DOI: 10.3748/wjg.v27.i33.5502] [Reference Citation Analysis]
45 Shousha HI, Ramadan A, Lithy R, El-Kassas M. Patterns of liver profile disturbance in patients with COVID-19 . World J Clin Cases 2022; 10(7): 2063-2071 [DOI: 10.12998/wjcc.v10.i7.2063] [Reference Citation Analysis]
46 Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time. Medicina (Kaunas) 2021;57:1057. [PMID: 34684094 DOI: 10.3390/medicina57101057] [Reference Citation Analysis]
47 Ahmad A, Ishtiaq SM, Khan JA, Aslam R, Ali S, Arshad MI. COVID-19 and comorbidities of hepatic diseases in a global perspective. World J Gastroenterol 2021; 27(13): 1296-1310 [PMID: 33833483 DOI: 10.3748/wjg.v27.i13.1296] [Reference Citation Analysis]
48 Mawson AR, Croft AM, Gonzalez-Fernandez F. Liver Damage and Exposure to Toxic Concentrations of Endogenous Retinoids in the Pathogenesis of COVID-19 Disease: Hypothesis. Viral Immunol 2021;34:376-9. [PMID: 33983857 DOI: 10.1089/vim.2020.0330] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Xiang TD, Zheng X. Interaction between hepatitis B virus and SARS-CoV-2 infections. World J Gastroenterol 2021; 27(9): 782-793 [PMID: 33727770 DOI: 10.3748/wjg.v27.i9.782] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]